David S Allan
Overview
Explore the profile of David S Allan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
106
Citations
1612
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Robertson P, Allan D, Garduno R
Biomolecules
. 2025 Jan;
15(1).
PMID: 39858485
HtpB, the chaperonin of the bacterial pathogen , is found in extracellular locations, even the cytoplasm of host cells. Although chaperonins have an essential cytoplasmic function in protein folding, HtpB...
2.
Parmar G, Green M, Ganz K, Seftel M, Allan D
Transfusion
. 2024 Sep;
64(11):2049-2054.
PMID: 39295246
Background: Allogeneic hematopoietic cell transplantation remains limited when stem cell registrants cannot be contacted, are not medically fit, are unavailable, or unwilling to proceed. In a recent report, registrants who...
3.
Parmar G, Seftel M, Ganz K, Blake J, Holovati J, Allan D
Curr Oncol
. 2024 May;
31(5):2542-2551.
PMID: 38785471
HLA-matched allogeneic hematopoietic cell transplantation (HCT) is a curative therapy for many patients. Unrelated HLA-matched donors are the most frequently used donor for HCT. When more than one donor transplant...
4.
Bennett B, Hanotaux J, Pasala A, Hasan T, Hassan D, Shor R, et al.
Cytotherapy
. 2024 Feb;
26(5):482-489.
PMID: 38416086
Background Aims: Cryopreservation of hematopoietic stem cells (HSCs) is crucial for autologous transplantation, cord blood banking and other special circumstances. Dimethyl sulfoxide (DMSO) is used most commonly for cryopreserving HSC...
5.
Hasan T, Pasala A, Hassan D, Hanotaux J, Allan D, Maganti H
Curr Oncol
. 2024 Feb;
31(2):603-616.
PMID: 38392038
Hematopoietic stem-cell (HSC) transplantation (HSCT) is used to treat various hematologic disorders. Use of genetically modified mouse models of hematopoietic cell transplantation has been critical in our fundamental understanding of...
6.
Seftel M, Pasic I, Parmar G, Bucher O, Allan D, Bhella S, et al.
Curr Oncol
. 2023 Nov;
30(11):9953-9967.
PMID: 37999143
Hematopoietic cell transplantation (HCT) is an established therapy for hematologic malignancies and serious non-malignant blood disorders. Despite its curative potential, HCT is associated with substantial toxicity and health resource utilization....
7.
Bailey A, Blake J, Ganz K, Seftel M, Allan D
Transfusion
. 2023 Sep;
63(11):2114-2119.
PMID: 37750668
Background: The utility of unrelated donor registries that support allogeneic hematopoietic cell transplantation could be optimized through greater understanding of redundancy and rareness of HLA phenotypes. Methods: HLA phenotype rareness...
8.
Duong A, Parmar G, Kirkham A, Burger D, Allan D
Cytotherapy
. 2023 May;
25(9):939-945.
PMID: 37191614
Background Aims: Interest in cell-based therapy using extracellular vesicles (EVs) is intensifying, building upon promising preclinical research and a handful of published clinical studies. Registered clinical trials remain small, heterogeneous...
9.
Parmar G, Allan D, Morris G, Dibdin N, Ganz K, Mostert K, et al.
Curr Oncol
. 2023 Mar;
30(3):3549-3556.
PMID: 36975483
Background And Objectives: The COVID-19 pandemic profoundly influenced unrelated donor (UD) allogeneic peripheral blood stem cell (PBSC) collections. Changes included efforts to minimize COVID-19 exposure to donors and cryopreservation of...
10.
Blake J, Parmar G, Ganz K, Seftel M, Allan D
Transfusion
. 2023 Mar;
63(5):1060-1066.
PMID: 36961333
Background: Human leukocyte antigen (HLA)-matched unrelated donors are not available for some patients considered for allogeneic hematopoietic cell transplantation, particularly among certain ethnic groups. Simulated recruitment modeling can inform efforts...